Abstract: The present invention provides methods for the diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessment/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the assessment of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different cardiac pathophysiological events and represent a potential target for therapeutical approaches.

Abstract: The present invention provides methods for the diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessment/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the assessment of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different cardiac pathophysiological events and represent a potential target for therapeutical approaches.

Abstract: The application discloses circRNAs as new biomarkers for the development of heart failure after myocardial infarction; methods for the prediction and diagnosis of heart failure are provided based on measuring said one or more circRNAs; and kits and devices for measuring said circRNAs and/or performing said methods. Further provided are methods for treating patients at risk of heart failure based on the evaluation of said one or more circRNAs.

Abstract: The application discloses circRNAs as new biomarkers for the diagnosis of heart failure, the prediction of the clinical evolution of heart failure and/or prediction of the response to a treatment in a patient; methods for the prediction of outcome and diagnosis of heart failure and/or predicting the response to a treatment are provided based on measuring said one or more circRNAs; and kits and devices for measuring said circRNAs and/or performing said methods. Further provided are methods for treating patients with heart failure based on the evaluation of said one or more circRNAs.

Abstract: The application discloses circRNAs as new biomarkers for the development of heart failure after myocardial infarction; methods for the prediction and diagnosis of heart failure are provided based on measuring said one or more circRNAs; and kits and devices for measuring said circRNAs and/or performing said methods. Further provided are methods for treating patients at risk of heart failure based on the evaluation of said one or more circRNAs.

Abstract: Provided is a method of identifying myocardially-infarcted patients having an increased risk of developing a heart condition.

Abstract: The present invention provides compositions and kits comprising miRNAs useful for the monitoring or diagnosis of heart disease in an individual. In particular, the compositions of the invention can be used for the prognosis of patients towards the development of left ventricular remodeling having suffered from an acute myocardial infarction. In addition, the present invention provides pharmaceutical compositions for the treatment of left ventricular remodeling.

Abstract: Provided is a method of identifying myocardially-infarcted patients having an increased risk of developing a heart condition.

Abstract: Uses for a selective adenosine A3 receptor antagonist, or RNAi directed against said receptor, to treat myocardial infarction and heart conditions including heart failure, are provided. Optionally, an adenosine A2a receptor agonist may also be used with the adenosine A3 receptor antagonist. Methods of treating heart failure are also provided.